Basic clinical variables, procedural variables and intraoperative measurements
| Basic clinical data and risk factors (n = 145 total), mean ± SD, n (%) . | |
|---|---|
| Gender (male) | 129 (89) |
| Height (cm) | 181 ± 9 |
| Weight (kg) | 90 ± 18 |
| NYHA I | 107 (74) |
| NYHA II | 29 (20) |
| NYHA III | 9 (6) |
| NYHA IV | 0 |
| Acute aortic dissection | 4 (3) |
| Bicuspid aortic valve | 21 (14) |
| ≥1 paracommissural fenestration | 145 (100) |
| Connective tissue disease | 32 (22) |
| Genetic testing confirmed CTD | 10 (7) |
| Previous cardiac procedure | 6 (4) |
| Cerebrovascular disease | 6 (4) |
| Prior stroke | 7 (5) |
| David I | 87 (60) |
| Modified David | 58 (40) |
| David IV | 23 (16) |
| David V Stanford | 34 (23) |
| Cusp defect repair attempt | 3 (2) |
| Cusp prolapse correction (pre-existing prolapse) | 28 (19) |
| Concomitant mitral repair | 6 (4) |
| Concomitant tricuspid repair | 3 (2) |
| Aortocoronary bypass | 14 (10) |
| Perfusion time (min) | 192 ± 55 |
| Cross-clamp time (min) | 149 ± 36 |
| TAV R/l height | 26 ± 4 mm |
| TAV R/N height | 28.5 ± 5 mm |
| TAV N/l height | 28.4 ± 5.1 mm |
| TAV free margin length LCC | 42 ± 6.1 mm |
| TAV free margin length RCC | 44.6 ± 7 mm |
| TAV free margin length NCC | 44.2 ± 6.6 mm |
| TAV effective height LCC | 12 ± 6.8 |
| TAV effective height RCC | 11.4 ± 6.5 mm |
| TAV effective height NCC | 12 ± 6.7 mm |
| TAV geometrical height LCC | 20.8 ± 4.6 mm |
| TAV geometrical height RCC | 20.9 ± 4.6 mm |
| TAV geometrical height NCC | 22 ± 4.2 mm |
| BAV R/l height | 21.1 ± 8.3 mm |
| BAV R/N height | 25.8 ± 6.7 mm |
| BAV N/l height | 25.7 ± 8.3 mm |
| BAV free margin length, fused | 42.6 ± 12.6 mm |
| BAV free margin length, nonfused | 47.3 ± 6.6 mm |
| BAV effective height, fused | 14 ± 5.3 mm |
| BAV effective height, nonfused | 16.4 ± 9 mm |
| BAV geometrical height, fused | 19.6 ± 3.6 mm |
| BAV geometrical height, nonfused | 23 ± 3.4 mm |
| Prosthesis size (mm) | 30 ± 3 mm |
| Hegar diameter annulus pre | 28.4 ± 2.5 mm |
| Hegar diameter annulus post | 25 ± 2 mm |
| New STJ post | 26.6 ± 2.4 mm |
| Effective height post (TEE) | 12 ± 3.6 mm |
| Coaptation height (TEE) | 9.3 ± 3.9 mm |
| Basic clinical data and risk factors (n = 145 total), mean ± SD, n (%) . | |
|---|---|
| Gender (male) | 129 (89) |
| Height (cm) | 181 ± 9 |
| Weight (kg) | 90 ± 18 |
| NYHA I | 107 (74) |
| NYHA II | 29 (20) |
| NYHA III | 9 (6) |
| NYHA IV | 0 |
| Acute aortic dissection | 4 (3) |
| Bicuspid aortic valve | 21 (14) |
| ≥1 paracommissural fenestration | 145 (100) |
| Connective tissue disease | 32 (22) |
| Genetic testing confirmed CTD | 10 (7) |
| Previous cardiac procedure | 6 (4) |
| Cerebrovascular disease | 6 (4) |
| Prior stroke | 7 (5) |
| David I | 87 (60) |
| Modified David | 58 (40) |
| David IV | 23 (16) |
| David V Stanford | 34 (23) |
| Cusp defect repair attempt | 3 (2) |
| Cusp prolapse correction (pre-existing prolapse) | 28 (19) |
| Concomitant mitral repair | 6 (4) |
| Concomitant tricuspid repair | 3 (2) |
| Aortocoronary bypass | 14 (10) |
| Perfusion time (min) | 192 ± 55 |
| Cross-clamp time (min) | 149 ± 36 |
| TAV R/l height | 26 ± 4 mm |
| TAV R/N height | 28.5 ± 5 mm |
| TAV N/l height | 28.4 ± 5.1 mm |
| TAV free margin length LCC | 42 ± 6.1 mm |
| TAV free margin length RCC | 44.6 ± 7 mm |
| TAV free margin length NCC | 44.2 ± 6.6 mm |
| TAV effective height LCC | 12 ± 6.8 |
| TAV effective height RCC | 11.4 ± 6.5 mm |
| TAV effective height NCC | 12 ± 6.7 mm |
| TAV geometrical height LCC | 20.8 ± 4.6 mm |
| TAV geometrical height RCC | 20.9 ± 4.6 mm |
| TAV geometrical height NCC | 22 ± 4.2 mm |
| BAV R/l height | 21.1 ± 8.3 mm |
| BAV R/N height | 25.8 ± 6.7 mm |
| BAV N/l height | 25.7 ± 8.3 mm |
| BAV free margin length, fused | 42.6 ± 12.6 mm |
| BAV free margin length, nonfused | 47.3 ± 6.6 mm |
| BAV effective height, fused | 14 ± 5.3 mm |
| BAV effective height, nonfused | 16.4 ± 9 mm |
| BAV geometrical height, fused | 19.6 ± 3.6 mm |
| BAV geometrical height, nonfused | 23 ± 3.4 mm |
| Prosthesis size (mm) | 30 ± 3 mm |
| Hegar diameter annulus pre | 28.4 ± 2.5 mm |
| Hegar diameter annulus post | 25 ± 2 mm |
| New STJ post | 26.6 ± 2.4 mm |
| Effective height post (TEE) | 12 ± 3.6 mm |
| Coaptation height (TEE) | 9.3 ± 3.9 mm |
BAV: bicuspid aortic valve; CTD: connective tissue disease; LCC: left coronary cusp; NCC: non coronary cusp; NYHA: New York Heart Association; RCC: right coronary cusp; SD: standard deviation; STJ: sinotubular junction; TAV: tricuspid aortic valve; TEE: transesophageal echocardiography.
Basic clinical variables, procedural variables and intraoperative measurements
| Basic clinical data and risk factors (n = 145 total), mean ± SD, n (%) . | |
|---|---|
| Gender (male) | 129 (89) |
| Height (cm) | 181 ± 9 |
| Weight (kg) | 90 ± 18 |
| NYHA I | 107 (74) |
| NYHA II | 29 (20) |
| NYHA III | 9 (6) |
| NYHA IV | 0 |
| Acute aortic dissection | 4 (3) |
| Bicuspid aortic valve | 21 (14) |
| ≥1 paracommissural fenestration | 145 (100) |
| Connective tissue disease | 32 (22) |
| Genetic testing confirmed CTD | 10 (7) |
| Previous cardiac procedure | 6 (4) |
| Cerebrovascular disease | 6 (4) |
| Prior stroke | 7 (5) |
| David I | 87 (60) |
| Modified David | 58 (40) |
| David IV | 23 (16) |
| David V Stanford | 34 (23) |
| Cusp defect repair attempt | 3 (2) |
| Cusp prolapse correction (pre-existing prolapse) | 28 (19) |
| Concomitant mitral repair | 6 (4) |
| Concomitant tricuspid repair | 3 (2) |
| Aortocoronary bypass | 14 (10) |
| Perfusion time (min) | 192 ± 55 |
| Cross-clamp time (min) | 149 ± 36 |
| TAV R/l height | 26 ± 4 mm |
| TAV R/N height | 28.5 ± 5 mm |
| TAV N/l height | 28.4 ± 5.1 mm |
| TAV free margin length LCC | 42 ± 6.1 mm |
| TAV free margin length RCC | 44.6 ± 7 mm |
| TAV free margin length NCC | 44.2 ± 6.6 mm |
| TAV effective height LCC | 12 ± 6.8 |
| TAV effective height RCC | 11.4 ± 6.5 mm |
| TAV effective height NCC | 12 ± 6.7 mm |
| TAV geometrical height LCC | 20.8 ± 4.6 mm |
| TAV geometrical height RCC | 20.9 ± 4.6 mm |
| TAV geometrical height NCC | 22 ± 4.2 mm |
| BAV R/l height | 21.1 ± 8.3 mm |
| BAV R/N height | 25.8 ± 6.7 mm |
| BAV N/l height | 25.7 ± 8.3 mm |
| BAV free margin length, fused | 42.6 ± 12.6 mm |
| BAV free margin length, nonfused | 47.3 ± 6.6 mm |
| BAV effective height, fused | 14 ± 5.3 mm |
| BAV effective height, nonfused | 16.4 ± 9 mm |
| BAV geometrical height, fused | 19.6 ± 3.6 mm |
| BAV geometrical height, nonfused | 23 ± 3.4 mm |
| Prosthesis size (mm) | 30 ± 3 mm |
| Hegar diameter annulus pre | 28.4 ± 2.5 mm |
| Hegar diameter annulus post | 25 ± 2 mm |
| New STJ post | 26.6 ± 2.4 mm |
| Effective height post (TEE) | 12 ± 3.6 mm |
| Coaptation height (TEE) | 9.3 ± 3.9 mm |
| Basic clinical data and risk factors (n = 145 total), mean ± SD, n (%) . | |
|---|---|
| Gender (male) | 129 (89) |
| Height (cm) | 181 ± 9 |
| Weight (kg) | 90 ± 18 |
| NYHA I | 107 (74) |
| NYHA II | 29 (20) |
| NYHA III | 9 (6) |
| NYHA IV | 0 |
| Acute aortic dissection | 4 (3) |
| Bicuspid aortic valve | 21 (14) |
| ≥1 paracommissural fenestration | 145 (100) |
| Connective tissue disease | 32 (22) |
| Genetic testing confirmed CTD | 10 (7) |
| Previous cardiac procedure | 6 (4) |
| Cerebrovascular disease | 6 (4) |
| Prior stroke | 7 (5) |
| David I | 87 (60) |
| Modified David | 58 (40) |
| David IV | 23 (16) |
| David V Stanford | 34 (23) |
| Cusp defect repair attempt | 3 (2) |
| Cusp prolapse correction (pre-existing prolapse) | 28 (19) |
| Concomitant mitral repair | 6 (4) |
| Concomitant tricuspid repair | 3 (2) |
| Aortocoronary bypass | 14 (10) |
| Perfusion time (min) | 192 ± 55 |
| Cross-clamp time (min) | 149 ± 36 |
| TAV R/l height | 26 ± 4 mm |
| TAV R/N height | 28.5 ± 5 mm |
| TAV N/l height | 28.4 ± 5.1 mm |
| TAV free margin length LCC | 42 ± 6.1 mm |
| TAV free margin length RCC | 44.6 ± 7 mm |
| TAV free margin length NCC | 44.2 ± 6.6 mm |
| TAV effective height LCC | 12 ± 6.8 |
| TAV effective height RCC | 11.4 ± 6.5 mm |
| TAV effective height NCC | 12 ± 6.7 mm |
| TAV geometrical height LCC | 20.8 ± 4.6 mm |
| TAV geometrical height RCC | 20.9 ± 4.6 mm |
| TAV geometrical height NCC | 22 ± 4.2 mm |
| BAV R/l height | 21.1 ± 8.3 mm |
| BAV R/N height | 25.8 ± 6.7 mm |
| BAV N/l height | 25.7 ± 8.3 mm |
| BAV free margin length, fused | 42.6 ± 12.6 mm |
| BAV free margin length, nonfused | 47.3 ± 6.6 mm |
| BAV effective height, fused | 14 ± 5.3 mm |
| BAV effective height, nonfused | 16.4 ± 9 mm |
| BAV geometrical height, fused | 19.6 ± 3.6 mm |
| BAV geometrical height, nonfused | 23 ± 3.4 mm |
| Prosthesis size (mm) | 30 ± 3 mm |
| Hegar diameter annulus pre | 28.4 ± 2.5 mm |
| Hegar diameter annulus post | 25 ± 2 mm |
| New STJ post | 26.6 ± 2.4 mm |
| Effective height post (TEE) | 12 ± 3.6 mm |
| Coaptation height (TEE) | 9.3 ± 3.9 mm |
BAV: bicuspid aortic valve; CTD: connective tissue disease; LCC: left coronary cusp; NCC: non coronary cusp; NYHA: New York Heart Association; RCC: right coronary cusp; SD: standard deviation; STJ: sinotubular junction; TAV: tricuspid aortic valve; TEE: transesophageal echocardiography.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
